Axsome, Earnings Call
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...
H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...
Axsome Therapeutics Inc. shares dipped over 2% on Tuesday — their worst session in nearly two weeks — after the company ...
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...
Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They ...
Needham raised the firm’s price target on Axsome Therapeutics (AXSM) to $153 from $133 and keeps a Buy rating on the shares. The company’s Q4 ...
Shares of Axsome Therapeutics ( AXSM -0.40%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.
Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...
Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback